Exthymic Secures $25M for Cell Therapy Manufacturing
Exthymic secured up to $25M to develop hospital-based manufacturing for engineered cell therapies.
Cell therapy manufacturing remains one of the biggest bottlenecks in advanced medicine.
What happened
Exthymic secured up to $25M to develop and test a device for hospital-based production of engineered cell therapies such as CAR-T. The goal is to make production safer, more reliable and closer to the point of care.
Why it matters
Current cell therapy manufacturing is expensive, complex and logistically difficult. Moving more production capability into hospitals could reduce turnaround times and make personalised therapies easier to deliver.
The bigger picture
The future of advanced medicine depends on manufacturing innovation as much as biology. Exthymic is targeting the infrastructure layer that could help cell therapies scale beyond specialised centres.